Bronchiolitis is a common lower respiratory infection (LRI) that primarily affects children under two years of age[@b1][@b2]. Respiratory syncytial virus (RSV) is recognized as the most important causative agent of bronchiolitis worldwide[@b3]. Typically, RSV epidemics occur in annual cycles and peak during the cold season in temperate climates and during the rainy season in warm climates[@b4].

During RSV epidemics, most infants become infected and develop mild disease. However, a fraction of children, between 2% and 3% of an age cohort, develop severe bronchiolitis that requires hospitalization[@b5]. RSV bronchiolitis is the most common infection-related cause of hospitalization among infants and young children in developed countries[@b6]. The only means of prevention is injecting high-risk children monthly with anti-RSV monoclonal antibody[@b7]. There is no vaccine or effective antiviral therapy available for RSV infection. Thus, treatment of bronchiolitis is mainly supportive and includes supplying oxygen and maintaining hydration[@b8].

There are several congenital and environmental risk factors, such as prematurity, immune deficiency, congenital heart disease, and tobacco smoke exposure, that predispose children to severe bronchiolitis[@b4]. However, the risk factors do not completely explain the variation in disease severity, and host genetic factors likely contribute to the severity of viral bronchiolitis. Some evidence of genetic susceptibility was provided by a twin study that showed a higher concordance in hospitalization rates between identical twins than in fraternal twins[@b9]. That study estimated the heritability of bronchiolitis to be 22%.

Genetic studies of susceptibility to bronchiolitis have mostly focused on variants in selected candidate genes, often related to immunity. A few studies have evaluated the relevance of larger groups of genes and have linked variations in the severity of RSV disease with innate immunity--related genes and the *IL13/IL4* locus in the 5q31 cytokine cluster[@b10][@b11]. Moreover, genetic studies have demonstrated RSV bronchiolitis--associated loci in genes encoding proteins such as toll-like receptors (TLRs), surfactant protein D (SFTPD), Vitamin D receptor (VDR), and various cytokines, of which some have been suggested in more than one study[@b3][@b10][@b12][@b13]. However, most genetic associations have not been replicated in subsequent studies.

Severe viral bronchiolitis during childhood, especially after RSV bronchiolitis or rhinovirus bronchiolitis, is associated with the development of asthma later in life[@b5][@b14]. It is unknown whether the risk of asthma increases because of the bronchiolitis or whether a common genetic background underlies both diseases[@b15]. Polymorphisms in genes including *IL-10, IL-13, TLR4, VDR, CCR5*, and *ADAM33* have been associated with both RSV bronchiolitis and a risk of asthma[@b16][@b17]. This may support a genetic predisposition to both infant viral bronchiolitis and subsequent asthma. An increased risk of childhood-onset asthma after rhinovirus infection has been associated with 17q21 locus[@b18].

Regarding bronchiolitis, genetic associations suggested in different studies need to be validated in further studies. A more comprehensive characterization of genetic determinants will lead to improved recognition of risk groups and will likely contribute to the development of new and more-specific treatments for respiratory infections. Therefore, the aim of the present study was to conduct a hypothesis-free genome-wide association study (GWAS) to identify genetic polymorphisms that predispose infants to viral bronchiolitis.

Results
=======

Suggestive associations in GWAS of bronchiolitis and RSV bronchiolitis
----------------------------------------------------------------------

We detected several suggestive association signals (*p* \< 1 × 10^−5^) in the GWAS performed on 217 infants hospitalized for viral bronchiolitis and 778 controls. ([Supplementary Figure S1](#S1){ref-type="supplementary-material"}). The stringent genome-wide significance level (*p* \< 5 × 10^−8^) was not reached. [Table 1](#t1){ref-type="table"} contains the results for the SNPs in the strongest suggestive GWA loci (*p* \< 5 × 10^−6^). Cases were stratified according to presence of RSV, and RSV-positive bronchiolitis cases (*n* = 121) were tested against the same GWAS controls ("RSV GWAS"). Again, the signals did not reach the level of genome-wide significance (*p* \< 5 × 10^−8^) ([Supplementary Figure S2](#S1){ref-type="supplementary-material"}). [Table 2](#t2){ref-type="table"} lists the strongest suggestive GWA loci (*p* \< 5 × 10^−6^) in the RSV GWAS. Three of the best loci were shared between the bronchiolitis GWAS and the RSV GWAS. The shared loci were situated in the regions near the genes *VSTM4, C10orf71*, and *DRGX* in chromosome 10 and in the region near *LOC105375265* and *LOC105375266* in chromosome 7. Based on the results obtained from the bronchiolitis GWAS and the RSV GWAS, we selected one representative SNP for the replication phase from each of the best suggestive GWA region. All SNPs selected for replication genotyping and the respective results are presented in [Supplementary Table S1](#S1){ref-type="supplementary-material"}.

SNPs associated with RSV bronchiolitis in previous studies
----------------------------------------------------------

We screened for SNPs that were reported to be associated with RSV bronchiolitis in previous studies and SNPs in the vicinity (within 20 kb) of such variants in our GWAS data. The exact SNPs reported in previous studies did not show associations or were not present in our GWAS data. The results for the variants near the reported bronchiolitis-associated SNPs are presented in [Supplementary Table S2](#S1){ref-type="supplementary-material"} (variants with *p* \< 0.01 in the bronchiolitis GWAS or RSV GWAS are shown). The best SNP was rs56039226 in the *CX3CR1* intron (*p* = 5.7 × 10^−5^). This SNP is located 11 kb upstream of the nonsynonymous *CX3CR1* variant, rs3732378 (previously T280M). The A-allele--containing genotypes of rs3732378 were associated with RSV bronchiolitis severity in a previous study by Amanatidou *et al*.[@b19]. The exact SNP was present in our GWAS data, but it did not show an association (*p* = 0.095). However, the A-allele was also slightly more frequent in the GWAS cases compared to the controls (allele frequencies of 0.16 and 0.14 in cases and controls, respectively).

SNPs associated with asthma in previous studies
-----------------------------------------------

When we screened SNPs that have been reported to be associated with asthma in the NHGRI-EBI GWAS Catalog (with *p* ≤ 10^−6^), no associations were seen in our data. The best SNP was rs12436663 (*p* = 5.8 × 10^−4^, OR = 1.96 for T allele in RSV GWAS) within *MRPP3* intron. The regions (20 kb) around the asthma-associated SNPs showed moderate signals in our data. The results are shown for variants with *p* ≤ 0.0001 in GWAS, RSV GWAS or GWAS with cases \<1year ([Supplementary Table S3](#S1){ref-type="supplementary-material"}). Many of the variants are known eQTLs. The variants showing strongest suggestive signals were in the area of *VCAN, HLA-DQA1*, and *NIN*. Those genes have various roles including cell adhesion, cytokine production, antigen binding and GTP binding[@b20].

Associations of rs269094, rs9591920, and rs1537091 with bronchiolitis in the replication populations
----------------------------------------------------------------------------------------------------

In the replication phase, we analyzed 77 of the most promising SNPs based on the results of the GWA analysis in an independent population collected in the Netherlands (416 cases and 432 controls). The suggestive associations of three of the SNPs (rs269094, rs9591920, and rs1537091) with bronchiolitis were nominally replicated (*p* \< 0.05), and meta-analysis for these SNPs yielded lower *p* values compared to the original GWAS ([Table 3](#t3){ref-type="table"}). The results were similar for the RSV GWAS and GWAS of infants aged \<1 year. The results for the SNPs with a *p* value \<0.1 in the Dutch population and ORs in the same direction in the GWAS subsets, and meta-analyses, are shown in [Supplementary Table S4](#S1){ref-type="supplementary-material"}.

To identify genes for which expression is potentially affected by our candidate SNPs (p value \< 0.05 in the Dutch replicate), we queried genotype-tissue expression (GTEx) data[@b21]. Rs269094 was previously identified as an eQTL for *KCND3* in spleen (*p* = 7.1 × 10^−10^); the C-allele is associated with higher expression. Another correlated SNP in the same region (rs269101, r^2^ = 0.42 in 1000 genomes phase3 Finnish individuals) showed a trend toward association in our GWAS (*p* = 4.2 × 10^−5^) and in the replicate (*p* = 0.054), further supporting the result. By exploring the NHGRI-EBI GWAS Catalog, we also discovered that variants in or near *KCND3* have been associated with diisocyanite-induced asthma and the cytokine response to smallpox[@b22]. The two other candidate SNPs were not identified as known eQTLs.

We further screened the three SNPs (with p \< 0.05 in the Dutch population) in the Finnish case data collected in Turku, using the NordicDB population controls as a reference ([Supplementary Table S5](#S1){ref-type="supplementary-material"}). Rs9591920 showed an association (*p* = 0.042, OR = 1.5). The allele frequencies of the two other SNPs, rs269094 and rs1537091, did not differ between cases and controls in this analysis.

Discussion
==========

In the present study, we identified several suggestive GWA loci associated with viral bronchiolitis. Three of the SNPs selected for replication genotyping showed nominal associations (p \< 0.05) also in an external replication population. Of those variants, rs269094 is a known eQTL for *KCND3*, which has been linked to diverse functions including regulation of neurotransmitter release and heart rate[@b20]. More recently, the gene has also been associated with diisocyanite-induced occupational asthma and cytokine response in smallpox vaccine recipients[@b23][@b24]. At the protein level, KCND3 interacts with another membrane protein, DPP10, of which genetic variants have been associated with conditions including asthma[@b20][@b25]. The association of another SNP with p \< 0.05 in the Dutch population, rs9591920, was nominally replicated in the additional Finnish case set. The variant resides within an uncharacterized noncoding RNA (ncRNA) locus (*LOC105370220*)[@b20]. Thus, it is difficult to assign potential functions to this region. In general, intergenic or noncoding SNPs have been associated with many complex phenotypes in previous GWASs. The SNPs within ncRNA loci could affect either the expression or function of the RNA molecule, which may further regulate target gene expression[@b26]. The third variant showing nominal association in the Dutch cohort, rs1537091, is located in an intergenic region, nearest loci being long intergenic non-protein coding RNAs without known function. Further study is required to validate the associations of our candidate variants and study their potential mechanism in bronchiolitis susceptibility.

We detected only modest signals for the regions around SNPs reported by previous studies to be associated with bronchiolitis. This might be due to allele frequency or LD structure differences among study populations, false discoveries by chance due to limited population size or gene-environment interactions. The confounding effect of population stratification is difficult to take into account in candidate gene studies; in the present study, we could account for the slight structure caused by differing genetic origins by exploiting the genome-wide data and principal components and thus reduce the risk of false-positive findings. Further, we could exclude population outliers and close relatives based on information provided by genome-wide sampling. In our data, the best variant near the SNP that was previously reported to be associated with bronchiolitis was in *CX3CR1* intron (*p* = 5.7 × 10^−5^).

Due to suggested shared genetic contribution among bronchiolitis and asthma, variants that have been associated with asthma in previous studies, and regions (20 kb) around the variants, were screened in our data. Moderate signals (p \< 0.0001) were detected in variants within genes including *VCAN* and *HLA-DQA1. HLA-DQ* region has been associated with different types of asthma in several studies[@b27], and an association of *VCAN* with asthma was discovered more recently[@b28]. Asthma clusters in families and likely has a strong genetic component, with heritability estimates as high as 60%[@b29]. Hundreds of genetic polymorphisms have been associated with different asthma phenotypes in past genetic studies. However, asthma is a complex and heterogeneous disease which is likely contributed by a combination of many genes in interaction with environmental factors[@b30]. Thus, the potential roles of the suggested genes in LRI susceptibility, and an overlap with biological pathways related to asthma, warrant further study.

The present study had several limitations. The sample size was relatively small, and thus especially the stratified GWAS subset analyses might have been underpowered. In the discovery GWAS, the best suggestive association signals, that were almost genome-wide significant, were seen in the area of *LOC105375265* on chromosome 7 and in the area of *VSTM4* and *DRGX* on chromosome 10. The signals in these regions were identified both in the GWAS and the RSV GWAS but not in the Dutch replication population. Despite the lack of replication, these signals might well reflect true associations in the Finnish population.

There is no worldwide consensus on treatment and diagnosis of bronchiolitis. The American Academy of Pediatrics defines 24 months as an upper age limit of bronchiolitis[@b2][@b31]. In Finland and Sweden, clinicians have begun to consider bronchiolitis to be mainly a disease of infants under 12 months of age[@b32]. In our GWAS, most of the cases were \<12 months of age at the time of the diagnosis. Moreover, for the most part the results for the GWAS \<1 year were similar to those of the main GWAS. However, the differing clinical definitions of included bronchiolitis cases were one limitation of the current study. Further limitation was the differing proportion of RSV positive samples between the GWAS and the replication populations. In studies to come, selecting bronchiolitis study cases according to more specified criteria will likely help detecting greater effects and susceptibility genes associated with specific phenotypes.

The present GWAS identified several variants that were suggestively associated with bronchiolitis. Although no significant associations were detected, our study provides the first genome-wide examination of bronchiolitis and a large body of data that may benefit future studies on complex genetic determinants and biological pathways that cause variation in bronchiolitis susceptibility. Further replication and functional validation is needed to verify and uncover the potential roles of our candidate SNPs. The relationship between infant viral bronchiolitis and asthma, and a plausible genetic overlap of the two diseases, remain an important area of study.

Materials and Methods
=====================

Study design and populations
----------------------------

The study populations comprised a total of 2045 study subjects consisting of 835 bronchiolitis cases and 1210 controls (974 females and 1071 males). The study was approved by the ethics committees of Tampere University Hospital and Kuopio University Hospital, Finland, and the regional ethics committee of Gothenburg, Sweden. The study was carried out in accordance with the approved guidelines of the WMA Declaration of Helsinki. Informed consents were obtained from the study subjects or provided by their parents. The main elements of the study were: (1) a GWAS in a Finnish--Swedish discovery population of 217 cases and 778 controls, (2) an analysis of the most promising variants in a Dutch replication population of 416 cases and 432 controls, and (3) a further examination of the most promising variants in an additional Finnish set of 202 cases. Moreover, GWAS cases were stratified according to age or presence of RSV and the subgroups of RSV positive cases ("RSV GWAS") and those of \<12 months of age were studied separately ([Fig. 1](#f1){ref-type="fig"}).

The inclusion criteria for all the affected children were (1) clinically diagnosed bronchiolitis, (2) an age \<24 months at the time of diagnosis and (3) native Finnish, Swedish or Dutch ethnicity. Bronchiolitis was defined as the presence of LRI and respiratory symptoms typical of bronchiolitis, including wheezing and labored breathing[@b2]. RSV infection was tested by antigen immunofluorescent or radioimmuno assays, viral isolation, PCR of nasopharyngeal cells or by serum antibody assays.

Overall, RSV was detected in 72% of the cases, and \>80% were under 12 months of age. Characteristics of bronchiolitis cases in GWAS discovery cohorts and validation cohorts are presented in [Tables 4](#t4){ref-type="table"} and [5](#t5){ref-type="table"}. The populations are further described in the [Supplementary Material](#S1){ref-type="supplementary-material"}. Briefly, the Finnish individuals (*n* = 936) in the GWAS discovery population originated from Kuopio (64 cases, 64 controls), Tampere (124 cases), and Helsinki/Kuopio (684 controls) regions[@b33][@b34][@b35][@b36]. A subset of the GWAS population was collected in Gothenburg, Sweden (29 cases, 30 controls)[@b37]. Replication cohorts originated from The Netherlands (*n* = 848) and Finland (*n* = 202)[@b10][@b38][@b39].

DNA sample preparation and genotyping
-------------------------------------

Genomic DNA was obtained from whole blood samples, buccal swabs, or buffy coats. DNA from blood samples collected from the GWAS subjects was extracted with the UltraClean^®^ Blood DNA Isolation Kit (MO BIO Laboratories, Inc., Carlsbad, CA, USA). DNA from infants in the Dutch replication cohort was isolated from blood samples or buccal swabs with the QIAamp DNA Blood Kit (Qiagen, Hilden, Germany). DNA extraction from buffy coats collected from the Dutch population controls was done by digestion with proteinase K followed by salting out with potassium acetate and chloroform--isoamyl alcohol extraction.

Genome-wide genotyping was performed with the Human Genotyping Array Kits (Illumina, San Diego, CA, USA. ([Supplementary Table S6](#S1){ref-type="supplementary-material"}). The Technology Centre at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki, did the genotyping. FIMM also performed the targeted SNP genotyping in the replication phase with the Sequenom iPLEX Gold assay (San Diego, CA, USA). NordicDB controls are described in detail in Bilguvar *et al*.[@b40].

Quality control and imputation of the genome-wide data
------------------------------------------------------

After quality control (QC), 995 study subjects were available for the analyses: 464 male subjects and 531 female subjects/217 cases and 778 controls. There were 79,563 autosomal SNPs with a MAF of \>0.01. The data was prephased with SHAPEIT2, followed by genotype imputation (i.e., statistical prediction of missing genotypes) with IMPUTE2[@b41][@b42]. More detailed description of the QC and imputation can be found in the online [Supplementary Material](#S1){ref-type="supplementary-material"}. After imputation, the amount of SNPs (MAF \>0.01) was 5,304,323.

Selection of SNPs for replication analysis
------------------------------------------

Seventy-seven SNPs were genotyped in the Dutch replication population. Because the stringent genome-wide significance level (*p* \< 5 × 10^−8^) was not reached in the discovery GWAS, less-strict criteria were applied for the selection of SNPs. *p* values of \<5 × 10^−4^ and \<1 × 10^−4^ for genotyped and imputed SNPs, respectively, were used as threshold values for suggestive associations. For imputed SNPs, linkage disequilibrium (LD) was taken into account by selecting relatively independent (r^2^ \< 0.5) SNPs from each suggestive GWA locus. Sporadic imputed SNPs were excluded. Provided that a suggestive GWA locus had several variants with similar *p* values, the best SNP was chosen based on predicted or empirical regulatory functions (including eQTLs, promoter activity, and protein binding sites) by exploring annotation databases, including HaploReg v. 4.1, GTEx, and dbSNP[@b21][@b43][@b44]. We did not choose low-frequency SNPs (MAF \<0.02 in cases or controls) in the main GWAS population to avoid genotyping monomorphic SNPs in the Dutch population. We tested the homogeneity of odds ratios among the GWAS subpopulations according to city of origin with the Breslow--Day test and excluded variants with *p* values of \<0.01.

Statistical analysis
--------------------

### Principal component analysis (PCA)

PCA with PLINK1.9 was performed on nonimputed LD-pruned GWAS data to delineate components explaining possible remaining population structure. The adequate number of components was evaluated based on genome-wide inflation factor lambda (λ), eigenvalues, and inspection of covariate significances in logistic regression. Three leading components were incorporated into subsequent association analyses.

### SNP association analysis

Allele frequency differences were assessed with logistic regression under an additive model, with gender and three principal components as covariates. Analyses were performed with PLINK 1.9[@b45]. Lambda values were close to 1, indicating an adequately controlled population structure (λ = 1.004 for the genotyped population, λ = 1.06 for the imputed population). In the RSV GWAS, we studied a subset of cases positive for RSV infection (*n* = 121) against the GWAS controls (*n* = 778). Similarly, cases that were \<12 months of age (173 cases, 778 controls) were tested as a group. Replication populations collected in the Netherlands and Turku, Finland, were studied with logistic regression analysis under an additive model, with gender as a covariate. Measures of basic QC, which entailed removing variants with MAF \<0.01, genotyping rate \<0.9, or deviation from HWE (*p* \< 0.001), were performed. The replication case set of Turku was studied against the NordicDB population controls (*n* = 684). The discovery and the Dutch replication population were studied by meta-analysis under a fixed-effects model to estimate their combined effect. Confidence intervals for odds ratios of meta-analysis were calculated with a meta package in R[@b46][@b47]. Finally, SNPs that were reported in the literature to be associated with RSV bronchiolitis or asthma, or variants within 20 kb of such SNPs, were screened in our GWAS data.
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###### Strongest suggestive GWA loci (*p* \< 5 × 10^−6^) identified by bronchiolitis GWAS and SNPs selected for replication genotyping from each locus.

  Suggestive GWA locus[╤](#t1-fn1){ref-type="fn"}              Selected SNP information                                                                                                                                            
  ------------------------------------------------- ----------------------------------------------- ----- ----- -------------- ------------- ----------- ------------------------------ ----- ------- ------- -------------------- --------------
  1                                                             246851155\.\.246968053               116   119   3.2 × 10^−6^   rs61202512    246860213  *SCCPDH, CNST*                   A    0.464   0.327   1.67 (1.32--2.11)    1.6 × 10^−5^
  2                                                             235168096\.\.235202022               33    29    2.8 × 10^−6^   rs11886348    235193436  *LOC105373933*                   G    0.079   0.027   3.35 (2.02--5.55)    2.8 × 10^−6^
  3                                                                5377711..5570764                  193   24    4.7 × 10^−6^   rs79062720     5442550   *MIR4790, EDEM1*                 C    0.064   0.021   3.79 (2.14--6.70)    4.7 × 10^−6^
  3                                                               39318192..39593234                 275   38    3.2 × 10^−6^   rs56039226    39318192   *CX3CR1*                         A    0.041   0.011   4.43 (2.15--9.14)    5.7 × 10^−5^
  3                                                             107206802\.\.107233889               27     6    3.0 × 10^−6^    rs6437736    107208688  *BBX, CCDC54*                    A    0.366   0.491   0.58 (0.47--0.73)    3.0 × 10^−6^
  3                                                             153780474\.\.153973898               193    9    5.0 × 10^−6^   rs36086140    153973898  *ARHGEF26*                       T    0.093   0.037   2.86 (1.82--4.48)    5.0 × 10^−6^
  4                                                               24735463..24736258                 0.8    2    2.6 × 10^−6^    rs4697072    24735463   *SOD3, CCDC149*                  G    0.410   0.532   1.77 (1.40--2.25)    2.6 × 10^−6^
  5                                                             167829645\.\.168048306               218    6    6.0 × 10^−7^    rs4976604    167849667  *WWC1*                           C    0.064   0.021   3.80 (2.15--6.71)    4.3 × 10^−6^
  7                                                  46319511..46524796[†](#t1-fn5){ref-type="fn"}   205    9    1.5 × 10^−7^   rs62452699    46492326   *LOC105375265, LOC105375266*     T    0.143   0.060   2.83 (1.92--4.17)    1.5 × 10^−7^
  10                                                 50452677..50460878[†](#t1-fn5){ref-type="fn"}    8    10    4.9 × 10^−7^   rs17009617    50453933   *VSTM4, C10orf71*                A    0.090   0.032   3.39 (2.11--5.46)    4.9 × 10^−7^
  10                                                 50454331..50553085[†](#t1-fn5){ref-type="fn"}   98    50    3.9 × 10^−7^   rs76728164    50465201   *C10orf71, DRGX*                 T    0.088   0.032   2.93 (1.86--4.62)    3.7 × 10^−6^
  10                                                 50454331..50553085[†](#t1-fn5){ref-type="fn"}   98    50    3.9 × 10^−7^    rs1001338    50498449   *C10orf71, DRGX*                 G    0.086   0.031   3.10 (1.95--4--93)   1.7 × 10^−6^
  10                                                            128584158\.\.128805211               221   12    2.1 × 10^−6^   rs111255454   128777619  *DOCK1*                          G    0.065   0.021   3.90 (2.22--6.84)    2.1 × 10^−6^
  12                                                              17376616..17514609                 137   37    3.8 × 10^−6^    rs2137526    17377995   *LOC105369677, LOC105369676*     T    0.233   0.148   1.98 (1.48--2.65)    3.8 × 10^−6^
  13                                                              59304857..59481192                 176   40    2.0 × 10^−6^    rs9591920    59315119   *LOC105370220*                   T    0.190   0.098   2.16 (1.57--2.97)    2.0 × 10^−6^
  13                                                              67847391..67877199                 29     4    4.6 × 10^−7^   rs142670120   67850108   *PCDH9, LOC105370246*           DEL   0.099   0.037   3.23 (2.05--5.10)    4.6 × 10^−7^
  16                                                              73130946..73140092                  9     5    2.4 × 10^−6^   rs76079505    73136490   *ZFHX3, C16orf47*                T    0.203   0.100   2.22 (1.59--3.09)    2.4 × 10^−6^
  17                                                              72973962..73220824                 246   12    2.1 × 10^−6^   rs113409681   72973962   *HID1, CDR2L*                    A    0.076   0.025   3.58 (2.11--6.05)    2.1 × 10^−6^
  20                                                              56486748..56527179                 40    12    1.3 × 10^−6^   rs379083\*    56527179   *MIR4532, LOC100129869*          T    0.112   0.043   2.82 (1.86--4.29)    1.3 × 10^−6^
  21                                                              42284256..42343366                 59    52    2.6 × 10^−6^   rs117674297   42343366   *DSCAM, BACE2*                   A    0.092   0.038   2.96 (1.88--4.65)    2.6 × 10^−6^

^╤^Each suggestive GWA locus comprises several SNPs in LD (r^2^ \> 0.5, *p* \< 0.01). Loci were formed with default options of LD-based result clumping (PLINK 1.9). We selected one variant for replication genotyping from each locus. Signals in sporadic imputed variants (not shown) were considered unreliable and not chosen for replication genotyping. Variants with a minor allele frequency of \<0.02 within either cases or controls were not chosen for replication genotyping.

^Ж^Range and location refer to human genome build 37 (GRCh37/hg19) coordinates.

^\*\*^Corresponding locus shown for variants within genes; two nearest loci shown for intergenic SNPs.

^‡^OR for A1 allele under additive model in logistic regression, with sex and three principal components as covariates.

^†^Suggestive GWA loci shared between GWAS and RSV GWAS (of loci with *p* \< 5 × 10^−6^).

GWA, genome-wide association; SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; LD, linkage disequilibrium.

###### Strongest suggestive GWA loci (*p* \< 5 × 10^−6^) from RSV bronchiolitis GWAS and SNPs selected for replication genotyping from each locus.

  Suggestive RSV GWA locus[╤](#t2-fn1){ref-type="fn"}              Selected SNP information                                                                                                                                         
  ----------------------------------------------------- ----------------------------------------------- ----- ---- -------------- ------------- ----------- ------------------------------ --- ------- ------- -------------------- --------------
  1                                                                 153512691\.\.153996110               483   6    5.2 × 10^−7^   rs75940909    153932075  *SLC39A1*                       A   0.063   0.011   5.58 (2.69--11.93)   9.2 × 10^−6^
  1                                                                 154011426\.\.154260767               249   4    1.1 × 10^−6^   rs186841738   154187935  *C1orf43*                       A   0.062   0.009   6.73 (3.02--15.01)   3.1 × 10^−6^
  2                                                                   36592600..36617435                 24    2    2.4 × 10^−6^   rs112913823   36617435   *CRIM1*                         G   0.086   0.025   4.38 (2.37--8.09)    2.4 × 10^−6^
  3                                                                 185675973\.\.185677613                1    9    4.9 × 10^−6^    rs6444089    185676350  *TRA2B, ETV5*                   G   0.277   0.410   0.48 (0.34--0.66)    8.7 × 10^−6^
  3                                                                 185675973\.\.185677613                1    9    4.9 × 10^−6^   rs55675198    185677613  *TRA2B, ETV5*                   G   0.252   0.391   0.46 (0.33--0.64)    6.2 × 10^−6^
  4                                                                   32653789..32869901                 216   52   4.7 × 10^−6^    rs4547837    32688632   *LOC107986223, LOC101927363*    T   0.054   0.010   6.55 (2.93--14.65)   4.7 × 10^−6^
  7                                                                  46319511..46524796^†^               205   9    6.9 × 10^−7^   rs62452699    46492326   *LOC105375265, LOC105375266*    T   0.149   0.061   3.37 (2.09--5.45)    6.9 × 10^−7^
  7                                                                 148765688\.\.148959272               193   21   5.5 × 10^−7^   rs139743624   148870713  *ZNF398*                        A   0.051   0.010   6.51 (2.86--14.86)   8.5 × 10^−6^
  10                                                     50452677..50460878[†](#t2-fn5){ref-type="fn"}    8    10   3.1 × 10^−7^   rs17009617    50453933   *VSTM4, C10orf71*               A   0.111   0.032   4.16 (2.41--7.19)    3.1 × 10^−7^
  10                                                     50454331..50553085[†](#t2-fn5){ref-type="fn"}   98    50   1.2 × 10^−7^   rs76728164    50465201   *C10orf71, DRGX*                T   0.106   0.033   3.46 (2.05--5.85)    3.6 × 10^−6^
  10                                                     50454331..50553085[†](#t2-fn5){ref-type="fn"}   98    50   1.2 × 10^−7^    rs1001338    50498449   *C10orf71, DRGX*                G   0.112   0.031   3.95 (2.33--6.69)    3.6 × 10^−7^
  15                                                                  39354517..39515134                 160   46   6.5 × 10^−7^   rs75360543    39505815   *LOC105370777*                  G   0.104   0.034   4.10 (2.35--7.14)    6.5 × 10^−7^

^╤^Each suggestive GWA locus comprises several SNPs in LD (r^2^ \> 0.5, *p* \< 0.01). Loci were formed with default options of LD-based result clumping (PLINK 1.9). We selected one variant for replication genotyping from each locus. Signals in sporadic imputed variants (not shown) were considered unreliable and not chosen for replication genotyping.

^Ж^Range and location refer to human genome build 37 (GRCh37/hg19) base pair positions.

^\*\*^Corresponding locus shown for variants within genes; two nearest genes shown for intergenic SNPs.

^‡^OR for A1 allele under additive model in logistic regression, with sex and three principal components as covariates.

^†^Suggestive GWA loci shared between GWAS and RSV GWAS (of loci with *p* \< 5 × 10^−6^).

GWA, genome-wide association; RSV, respiratory syncytial virus; SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; LD, linkage disequilibrium.

###### SNPs that had a *p* value of \<0.05 in the Dutch replicate, with ORs in the same direction compared to GWAS.

  Variant details    GWAS   Replication  Meta-analysis[§](#t3-fn5){ref-type="fn"}                                                                                           
  ----------------- ------ ------------- ------------------------------------------ --- ------------------- -------------- ------------------- -------- ------------------- --------------
  rs269094            1      112639174   *KCND3, LOC643355*                          C   1.67 (1.30--2.15)   5.3 × 10^−5^   1.28 (1.03--1.60)   0.0292   1.44 (1.22--1.70)   1.5 × 10^−5^
  rs9591920           13     59315119    *LOC105370220*                              T   2.16 (1.57--2.97)   2.0 × 10^−6^   1.41 (1.05--1.88)   0.0227   1.71 (1.38--2.12)   9.8 × 10^−7^
  rs1537091           21     29004226    *LOC105372763, LINC00113*                   A   1.69 (1.34--2.14)   1.3 × 10^−5^   1.24 (1.01--1.52)   0.0408   1.42 (1.21--1.66)   1.1 × 10^−5^

^Ж^Location refers to human genome build 37 (GRCh37/hg19) coordinates.

^\*\*^Corresponding locus shown for variants within genes; two nearest genes shown for intergenic SNPs.

^‡^OR for A1 allele under additive model in logistic regression, with sex and three principal components as covariates.

^╤^OR for A1 allele under additive model in logistic regression, with sex as a covariate.

^§^Meta-analysis performed under fixed-effects model for logistic regression result files of discovery and replication data.

SNP, single nucleotide polymorphism; GWAS, genome-wide association study; RSV, respiratory syncytial virus; OR, odds ratio; CI, confidence interval; Chr, chromosome.

###### Characteristics of study cases in GWAS bronchiolitis populations.

                          All   Kuopio, FIN   Tampere, FIN   Gothenburg, SWE                    
  ---------------------- ----- ------------- -------------- ----------------- ----- ------ ---- ------
  All cases               217      100%            64             100%         124   100%   29   100%
  RSV positive            121       56%            21              33%         90    73%    10   36%
  RSV negative            94        43%            41              64%         34    27%    19   64%
  Age \<12 months         173       80%            33              52%         124   100%   16   55%
  Age \>12 months         42        19%            29              45%          0     0%    13   45%
  Males                   114       53%            36              56%         62    50%    16   55%
  Hospitalization rate             100%                           100%               100%        100%

GWAS, genome-wide association study; FIN, Finland; SWE, Sweden.

###### Characteristics of bronchiolitis cases in replication populations.

                                              Netherlands            Turku, Finland                  
  ------------------------------------------ ------------- ----------------------------------- ----- ------
  All cases                                       416                     100%                  202   100%
  RSV positive[\*](#t5-fn1){ref-type="fn"}        416                     100%                  62    31%
  Males                                           237                      60%                  140   69%
  Age \<12 months                                           95%[\*\*](#t5-fn2){ref-type="fn"}         50%
  Hospitalization rate                                                    100%                        90%

^\*^Only RSV-positive bronchiolitis cases originally selected[@b10].

^\*\*^Cases were randomly acquired from a population of \>95% of the cases \<12 months of age[@b10].

[^1]: These authors contributed equally to this work.
